JOURNAL LE REFLETBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL LE REFLET
Company Title:
Company Description:
Keywords to Search:
Company Address:	2015 Laurier St,ROCKLAND,ON,Canada
ZIP Code: Postal Code:	K4K1K5
Telephone Number:	6134461446
Fax Number:
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	271101
USA SIC Description:	Newspapers (Publishers)
Number of Employees:	1 to 4
Sales Amount:	Less than $500,000
Credit History: Credit Report:	Very Good
Contact Person:	Odette Saumure
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
JOURNAL VISION
JOURNAL VISION
JOURNAL LE REFLET

Next company profile:
JOSTENS CANADA OTTAWA REGIONAL OFFICE
JEAN-MARC LALONDE DEPUTE
JEAN COUTU

Company News:

The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or progressed during or after
Encorafenib, Cetuximab, and mFOLFOX6 in - The New England Journal of . . .
First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream . . .
Bloodstream infections are associated with substantial morbidity and mortality Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain In a multicenter, non
Medical Management and Revascularization for Asymptomatic Carotid . . .
Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred management of asymptomatic carotid stenosis Whether adding revascularization t
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day 1 and
Zongertinib in Previously Treated - The New England Journal of Medicine
Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC) Zongertinib is an oral